Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

Hiromichi Miyagaki , Masahiro Goto , Shunji Endo , Ryo Tanaka , Takeshi Omori , Junji Kawada , Naoki Takahashi , Toru Masuzawa , Haruna Furukawa , Yuya Sato , Takeshi Kato , Kazumasa Fujitani, Hisato Kawakami , Daisuke Sakai , Yukinori Kurokawa , Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh

ASCO 2024　Chicago 31May – 4Jun 2024